8 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 11 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Human Immunodeficiency Virus (HIV): new trials by email Literature Review of Human Immunodeficiency Virus (HIV) trials Research Report on Human Immunodeficiency Virus (HIV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Not yet recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-11-01 | 2026-08-11 |
| Reducing Systemic Inflammation in People on Antiretroviral Therapy Fostemsavir - Human Immunodeficiency Virus (HIV), Cardiovascular Risk Factor | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 150 | 2025-09-30 | 2025-11-19 |
| The Effect of Ixazomib on the Latent HIV Reservoir Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG - Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | Completed | Mayo Clinic | 17 | 2017-03-20 | 2022-01-06 |
| Romidepsin Plus 3BNC117 Phase 2a Study 3BNC117, Romidepsin - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | Rockefeller University | 48 | 2017-01-06 | 2022-07-14 |
| An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study PRO 140 - Human Immunodeficiency Virus (HIV) | Phase 2 / Phase 3 | Terminated | CytoDyn, Inc. | 43 | 2016-11-03 | 2025-11-12 |
| Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis Rilpivirine, Placebo - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | PATH | 136 | 2014-10-01 | 2018-08-27 |
| Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART SB-728mR-T, Cyclophosphamide - Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 8 | 2014-08-01 | 2021-03-19 |
| Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults Quadrivalent Live Attenuated Influenza Vaccine - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | University of Colorado, Denver | 101 | 2013-07-01 | 2017-11-20 |
| Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Fluzone High Dose, Fluzone - Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder | Phase 2 | Completed | University of Colorado, Denver | 16 | 2012-09-01 | 2018-01-23 |
| A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Etravirine, Ritonavir, Darunavir - Human Immunodeficiency Virus (HIV) | Phase 2 | Completed | Tibotec, Inc | 54 | 2010-05-01 | 2013-12-04 |
| Study of Vitamin D and Effect on Heart Disease and Insulin Resistance Vitamin D, Placebo - Human Immunodeficiency Virus (HIV), Vitamin D Deficiency | Phase 2 | Completed | University Hospitals Cleveland Medical Center | 45 | 2010-01-01 | 2016-07-14 |
Acquired Immunodeficiency Syndrome (11) · Amphetamine-Related Disorders (1) · Collagen Diseases (1) · HIV Infections (1) · Vitamin D Deficiency (1)
Blood-Borne Infections (11) · Communicable Diseases (11) · Genital Diseases (11) · Immune System Diseases (11) · Immunologic Deficiency Syndromes (11) · Infections (11) · Lentivirus Infections (11) · RNA Virus Infections (11) · Retroviridae Infections (11) · Sexually Transmitted Diseases (11) · Sexually Transmitted Diseases, Viral (11) · Slow Virus Diseases (11) · Urogenital Diseases (11) · Virus Diseases (11) · HIV Infections (10)
3BNC117 antibody (1) · Antibodies, Monoclonal (1) · Cholecalciferol (1) · Cyclophosphamide (1) · Darunavir (1) · Fluzone High-Dose (1) · Histone Deacetylase Inhibitors (1) · Influenza Vaccines (1) · Motivational Interviewing (1) · Psilocybin (1) · Rilpivirine (1) · Ritonavir (1) · Vitamin D (1) · etravirine (1) · fostemsavir (1)
University of Colorado, Denver (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · CytoDyn, Inc. (1) · Mayo Clinic (1) · Nicky Mehtani, MD, MPH (1) · PATH (1) · Rockefeller University (1) · Sangamo Therapeutics (1) · Tibotec, Inc (1) · University Hospitals Cleveland Medical Center (1)
United States (9) · Canada (1) · Denmark (1) · Germany (1) · Puerto Rico (1) · South Africa (1) · Zimbabwe (1)
Adriana Weinberg, MD (1) · Donna Curtis, MD, MPH (1) · Donna Curtis, MD,MPH (1) · Jacob Lalezari, MD (1) · Jessica Justman, MD (1) · Linda-Gail Bekker, PhD (1) · Madeleine Durand, MD MSc FRCPC (1) · Marina Caskey, MD (1) · Myron Levin, MD (1) · Nathan Cummins, MD (1) · Nicky J. Mehtani, MD, MPH (1) · Shobha Swaminathan, MD (1) · Zvavahera Michael Chirenje, MD, MSc (1)
PMID 22293363, PMID 25585528, PMID 31651098, PMID 32838558, PMID 33191765, PMID 35544074
1DP2DA066200 (1), UM1AI068619 (1)